Status:
COMPLETED
12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking sta...
Eligibility Criteria
Inclusion
- Subjects must have smoked an average of at least ten cigarettes per day during the past year
- No period of abstinence greater than three months in the past year
Exclusion
- Subjects with history of clinically significant cardiovascular disease
- Subjects with uncontrolled hypertension.
Key Trial Info
Start Date :
December 1 2001
Trial Type :
INTERVENTIONAL
End Date :
September 1 2002
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00150228
Start Date
December 1 2001
End Date
September 1 2002
Last Update
June 4 2007
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Lexington, Kentucky, United States
2
Pfizer Investigational Site
Albert Lea, Minnesota, United States
3
Pfizer Investigational Site
Rochester, Minnesota, United States
4
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States